SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today increased availability of APP Diprivan® (propofol 1%) and APP Propofol 1% (authorized generic Diprivan®). Both are now readily available and APP has the supply necessary to meet the clinical needs of health care professionals.
